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REVIEW
marker might be a composite of several factors combined 
mathematically. However, for the purposes of this review, 
the focus is on measurement of expression or levels of 
 interleukin-6 (IL-6) and related proteins or factors that are 
directly controlled by IL-6, such as the acute phase reactant 
C-reactive protein (CRP). It is important to consider that a 
measurable factor may also be a surrogate marker, defined 
as “a laboratory measurement or physical sign that is used 
in therapeutic trials as a substitute for a clinically meaning-
ful end point that is a direct measure of how a patient feels, 
functions, or survives and is expected to predict the effect 
of the therapy” (1).
The need is great for biomarkers in systemic sclerosis 
(SSc) to help stratify patients, identify potential subgroups for 
treatment, and assess response to therapy. This is because 
SSc is a multisystem disease with variable clinical severity 
and outcome. Therefore, measures that can reflect this are of 
substantial potential value for the assessment and evaluation 
of patients. At present, objective measures of organ function 
(such as pulmonary function tests) and of renal function and 
clinical tools (such as modified Rodnan skin score) are avail-
able (2), but laboratory measures could be used to assess 
disease and determine the impact of treatment. It is also pos-
sible that such markers might be pathogenic mediators and 
targets for therapy. In this article, the extent to which this is 
true for IL-6 will be reviewed.
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Biomarkers and systemic sclerosis
There are substantial advantages to having measurable 
objective factors that reflect the severity or activity of a dis-
ease and modification by treatment. This led to the defini-
tion of biomarker. In 2016, the National Institutes of Health 
Biomarkers Definitions Working Group defined a biomarker 
as “a defined characteristic that is measured as an indica-
tor of normal biological processes, pathogenic processes, or 
responses to an exposure or intervention, including thera-
peutic interventions” (1). Biomarkers are not necessarily 
single entities that can be measured in biological samples; 
they might also be imaging data or other measurable fac-
tors, such as biomechanical properties (1). In addition, a 
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The search for biomarkers in systemic sclerosis (SSc) is driven by a goal to stratify patients, identify potential sub-
groups for treatment, and help assess response to therapy. Emerging evidence indicates that interleukin-6 (IL-6) 
and some family members are key biomarkers involved in SSc pathogenesis and therefore suitable targets for 
therapy. Recent studies evaluating IL-6 and its canonical Janus kinase/signal transducers and activators of tran-
scription downstream pathways in modulating fibrotic response and immune cell function suggest a pivotal role 
for IL-6 in SSc pathogenesis. Although the significance and effect of local tissue expression of IL-6 and its family 
members are less well established, high levels of circulating IL-6 may identify subgroups of patients with early-
stage disease, particularly those at risk for progressive lung fibrosis. In addition, higher disease activity may por-
tend poor prognostic outcome in terms of survival and skin disease. Longitudinal assessment of serum levels of 
IL-6 and its signaling associates may prove valuable in monitoring response to treatment. As an IL-6–dependent 
surrogate marker, C-reactive protein may assist cohort enrichment if targeted treatment for IL-6 demonstrates 
efficacy, especially in subgroups with high IL-6 levels. Although IL-6 appears to be a key factor in the hierarchy of 
the complex network of disease-associated molecules, the systemic or autocrine/paracrine manner in which IL-6 
asserts its profibrotic effects—particularly its interaction with other key pathogenic factors in SSc—is unknown. 
Ongoing clinical trials will help to delineate the mechanisms of IL-6 in SSc pathogenesis and inform on the role of 
these biomarkers.
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Studies of circulating CRP and IL-6 in SSc
Although SSc is a prototypic fibrotic disease with sys-
temic vasculopathy, it has been recognized that markers 
of inflammation are important prognostic indicators. Thus, 
erythrocyte sedimentation rate (ESR) has been shown to 
correlate with poor survival and to be a predictor of poor 
outcome (3, 4). Analogously, it is expected that CRP also 
predicts outcome, and appreciation that CRP is generally a 
reflection of IL-6 levels adds further weight to this potential 
link. This association was shown more recently and robustly 
by a study from the Canadian Scleroderma Research Group 
(5). In this study of more than 1000 patients, CRP levels 
were elevated in approximately one-quarter of patients. 
This correlated, as expected, with ESR but was also more 
likely to be elevated in patients with early-stage disease or 
with higher skin score, worse lung function, and greater dis-
ease activity and severity. These findings are in line with the 
effects of IL-6 levels on SSc reported by Hasegawa et al (6), 
who showed in 1998 that IL-6 levels correlated with CRP and 
ESR and that levels were especially elevated in early diffuse 
SSc and were associated with lung fibrosis. This study built 
on earlier studies in 1992 (7) that reported increased se-
rum levels of IL-2, IL-4, and IL-6 in SSc but lacked detailed 
investigation. Hasegawa et al (8) went on to show that there 
was enhanced production of IL-6 by peripheral blood mono-
nuclear cells (PBMCs) in SSc, suggesting that these cells may 
be an important source of IL-6 in the circulation. Recent 
studies have further defined differential IL-6 expression by 
PBMCs, in particular B-cell subsets, in SSc (9). In contrast to 
later studies, Hasegawa et al (8) reported that there was an 
apparent difference in soluble IL-6 receptor (sIL-6R) in SSc 
but no difference for gp130. The link between CRP and IL-6 
levels was shown more robustly in studies that used the bet-
ter high-sensitivity CRP assays. In a comprehensive study of 
IL-6, CRP, and sIL-6R levels in a cohort of patients with SSc 
by Khan et al in 2012 (10), there was clear confirmation of 
the  association between IL-6 and CRP and between IL-6 and 
elevated platelet counts (Fig. 1). This study (10) also demon-
strated increased tissue expression of IL-6 in relevant sites 
that strengthened the possible pathogenic role of IL-6 and 
built on previous in vitro studies (11) that had suggested 
overproduction of IL-6 by SSc fibroblasts. Therefore, it is 
clear that acute phase markers, driven at least in part by IL-6, 
are important prognostic markers in SSc. The availability 
of these surrogates for IL-6 levels that are routinely clini-
cally available has helped to enrich cohorts in trials and may 
ultimately be valuable in disease management if targeted 
treatment for IL-6 becomes available and is more effective 
in subgroups of patients with higher IL-6 levels.
Circulating and tissue IL-6 and organ-based disease  
in ssc
Although the studies described are of interest in SSc, it 
is more relevant to outcomes if IL-6 and related serum pro-
teins are reflective of organ-based complications. One of the 
first reports highlighted possible association between ele-
vated IL-6 levels and lung fibrosis in a cross-sectional study 
of patients with SSc (12). Interestingly, those investigators 
also found elevated levels of other cytokines and explored 
their expression from activated PBMCs and T cells. Building 
on this was the study by Beirne et al (13) that used a novel 
multiplex approach to determine patterns of elevated cyto-
kine and chemokine levels associated with lung fibrosis in 
patients with SSc. These patients were compared with other 
cohorts of patients, and it was notable that although no in-
dividual cytokine was predictive in this analysis, there was 
a trend for IL-6 and monocyte chemoattractant protein-1 
(13). This trend was later explored in a larger validation co-
hort because a threshold level of IL-6 was associated with 
significant lung fibrosis, and the results of this landmark 
Fig. 1 - Serum IL-6 levels in patients with SSc and in healthy controls. (A) Serum IL-6 levels in patients with SSc are increased compared with levels 
in healthy controls. Serum samples were obtained from patients with dcSSc (n=39; 20 with thrombocytosis), lcSSc (n=29), and healthy controls 
(n=15). For each subgroup, the median values are shown adjacent to the horizontal grey bars. (B) Serum IL-6 levels were correlated with CRP in 
patients with SSc (n=68). CRP = C-reactive protein; dcSSc = diffuse cutaneous SSc; IL-6 = interleukin-6; lcSSc = limited cutaneous SSc; SSc = systemic 
sclerosis. Adapted by permission from BMJ Publishing Group Limited. Annals of the Rheumatic Diseases, Khan K, Xu S, Nihtyanova S, et al., Vol. 
71, Pages 1235-1242, Copyright 2012.
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study defined the association between elevated IL-6 lev-
els in initial samples and the development of lung fibrosis 
and disease progression (14). Patients with relatively pre-
served lung function, represented by forced vital capacity 
(FVC) more than 70% predicted, experienced higher mor-
tality rates and greater risk for disease progression if they 
also had higher IL-6 levels. In contrast, in patients likely to 
have more advanced lung fibrosis, reflected by FVC less than 
70% predicted, there was no predictive value of serum IL-6. 
These results are interesting because they suggest that IL-6 
in serum may be more relevant in milder or earlier stage 
lung disease and also because FVC 70% has emerged as a 
predictive threshold for more severe disease that may re-
quire treatment with immunosuppressants (15). This obser-
vation is notable because emerging evidence from clinical 
trials suggests that IL-6R blockade may reduce the risk for 
significant worsening of lung function over 24 or 48 weeks 
of treatment. In line with this result is the observation by 
Liu et al (16) that CRP levels are associated with long-term 
progression and survival in SSc-associated lung fibrosis. In 
this study, not only were CRP levels higher in 266 patients 
with SSc compared with 97 controls (the GENISOS cohort), 
but CRP levels were associated with the absence of anticen-
tromere antibodies and correlated with the concomitant se-
verity of lung, skin, and joint involvement. Higher CRP levels 
were associated with shorter survival (p<0.001) and predict-
ed the long-term decline in FVC independent of potential 
confounders (age at baseline, sex, ethnicity, disease type, 
current smoking, body mass index, topoisomerase status, 
and treatment with immunosuppressive agents) in a multi-
variable model (p=0.006).
A broader analysis of the relationship between serum 
IL-6 and organ-based disease in SSc showed a link with 
measures of cardiorespiratory severity, including exercise 
capacity, pulmonary arterial estimated pressure, and lung 
fibrosis score (17). This is in line with earlier reports that IL-6 
was associated with cardiac complications (18), albeit in a 
relatively small study of 31 patients with SSc and matched 
controls. Correlation with left ventricular function and 
N-terminal probrain natriuretic peptide was notable, though 
there was no correlation with echocardiographic measures 
of pulmonary or right ventricular function. These patients 
were not selected for pulmonary hypertension, so this may 
not be surprising. Similarly, the emerging interest in IL-6 
in pulmonary arterial hypertension (PAH) is supported by 
early studies supportive of increased circulating levels (19, 
20), and IL-6R blockade has been explored in a clinical trial 
for SSc-associated PAH (ClinicalTrials.gov, NCT02676947). 
The link between serum IL-6 and gastrointestinal (GI) dis-
ease is less clear because cases have been reported in 
which IL-6R antagonists may worsen GI disease (21). How-
ever, this connection seems unlikely based on much larger 
prospective trials that have not identified worsening of GI 
complications (22).
Taken together, the data do support a role for IL-6 in mark-
ing and possibly mediating organ-based complications in SSc. 
This is interesting given that hierarchical clustering and net-
work analysis of dermal interstitial fluid identified a subset of 
patients with early-stage diffuse SSc with an innate inflamma-
tory IL-6–associated profile (23).
IL-6 in the skin in scleroderma – morphea and related 
disorders
Studies of localized scleroderma (morphea) provide some 
of the best evidence that serum IL-6 levels may be reflective 
of local skin disease. Results are conflicting, however, with 
some studies reporting no evidence of elevated levels of 
IL-6 in morphea (24) and other, much earlier, studies report-
ing evidence of elevated IL-6 levels (25), suggesting that the 
stage and extent of morphea are most likely to be relevant. 
The most recent study (26) used modern multiplex analysis 
to examine 63 cytokines or growth factors in a cohort of pa-
tients with morphea and had positive results; therefore, it 
does seem possible that IL-6 is a marker of and a mediator 
in morphea. In that study, 63 cytokines, chemokines, and 
growth factors were measured in the sera of four patients 
with idiopathic morphea and of one patient with vitamin K1–
induced morphea using a multiplex assay to identify the role 
of inflammatory/immunologic events in their pathogenesis. 
Full-thickness skin biopsy samples of affected skin were ana-
lysed by histopathology. Serum levels of IL-2, IL-4, IL-6, and 
interferon-β were markedly increased in the sera of patients 
with idiopathic morphea. However, the number of patients in 
this study is probably too small to draw strong conclusions.
IL-6 may be present and produced locally in SSc, as sup-
ported by analysis of dermal interstitial fluid and immuno-
histochemical evidence of local expression in affected skin, 
renal tissue, and pulmonary tissue (Fig. 2). In addition, some 
studies confirm a link with dermal interstitial fluid. Khan et al 
(10) showed that IL-6 levels may reflect long-term outcomes 
in skin and that elevated IL-6 levels could be a surrogate 
marker for clinical outcome for the subgroup of non-improver 
patients who have the worst skin trajectory, as identified in 
2007 by Shand et al (27).
IL-6 changes in SSc interventional trials
Although the cross-sectional studies described have 
shed some light on the value of IL-6 and CRP in the assess-
ment of SSc and localized scleroderma, there are many more 
informative and compelling data from longitudinal sampling 
in interventional trials. These trials have the value of sam-
pling over time and may link the clinical changes in skin and 
internal organs with changes in soluble IL-6 and CRP levels. 
One of the most promising studies is the faSScinate clinical 
trial, which used IL-6 targeting for the treatment arm with 
a neutralizing antibody against IL-6R. Interestingly, although 
the cohort-enrichment strategies for this study recruited a 
group of patients with high baseline IL-6 levels, there was 
an initial increase in IL-6 levels that reduced with repeated 
dosing (22). Other studies show changes in IL-6 levels, such 
as with rituximab (RTX) treatment. Thus, in a series of 10 
patients reported by Giuggioli et al (28), IL-6 levels were re-
duced after treatment in three of those patients with diffuse 
cutaneous SSc who had increased IL-6 at baseline. Consis-
tent with those findings, Bosello et al (29) reported nine pa-
tients with SSc who had reduced levels of IL-6 in serum that 
were associated with reduction in skin score and severity 
index after treatment with RTX (29). A clinical trial of ultra-
violet A1 phototherapy in 14 patients with morphea showed 
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a reduction in mRNA for IL-6 and other inflammatory or pro-
fibrotic cytokines (30). Reports of other clinical trials that did 
not specifically target IL-6 also indicate changes associated 
with improved skin scores. This was not seen in a study of 
imatinib, which instead showed no evidence of benefit for 
this treatment and evidence of substantial toxicity (31). In 
a trial of hyperimmune caprine serum, skin scores did im-
prove and IL-6 was among the serum cytokines whose levels 
decreased during therapy, thereby indicating it as a possible 
marker of skin change (32).
Links between IL-6 as a biomarker and its role in 
pathogenesis
The studies discussed here all point toward elevated IL-6 
expression and activity in the skin or sera of patients with SSc, 
providing a plausible mechanistic link to pathogenesis given 
that IL-6 has been shown to be profibrotic and to modulate 
immune cell function in ways that are relevant to SSc patho-
genesis. It is well established that the IL-6 trans-signaling 
pathway is pivotal in stromal cells, such as fibroblasts, which 
do not express membrane IL-6R, unlike some immune cells, 
such as macrophages and CD4 T cells, which are able to di-
rectly respond to IL-6. Activation of the key IL-6 downstream 
signaling Janus kinase/signal transducers and activators of 
transcription pathway in lesional tissue lends further support 
to the role of IL-6 in disease pathogenesis (10). Similar to pro-
fibrotic fibroblasts, these immune cells, which are important 
candidates in the development of SSc, can produce IL-6, rais-
ing the possibility that as well as being used as a marker or 
even a surrogate in SSc trials, IL-6 is a logical pathogenic me-
diator and a target for therapy. Although IL-6 appears to be a 
key factor in the hierarchy of a complex network of disease-
associated molecules, the systemic or autocrine/paracrine 
way in which IL-6 asserts its effects, particularly the activa-
tion of dermal fibroblasts, is unknown, and the mechanism 
of the role of IL-6 should be better defined and will likely be 
informed by recently completed and ongoing clinical trials.
IL-6 in context; other members of the IL-6 family in 
SSc and their potential as markers and mediators
Among the 10 known members of the IL-6 family of cyto-
kines, several have been reported to have altered expression 
levels in patients with SSc. Thus, in addition to the altered ex-
pression of IL-6 that is described in this article, some reports 
suggest that oncostatin M (OSM) is increased in SSc (Tab. I). 
Based on its diverse biological functions, including endothe-
lial activation, cellular proliferation, migration and differen-
tiation of fibroblasts, induction of acute phase responses, 
and wound healing, OSM may represent a candidate target 
for therapy. This is further supported by reports of increased 
expression of OSM in the circulation and lesional tissue of pa-
tients with SSc (33-36). A clinical trial of an anti-OSM thera-
peutic antibody is under way (ClinicalTrials.gov identifier, 
NCT02386436).
Although IL-11 shares many characteristics with IL-6, in-
cluding its effect on megakaryocytopoiesis and induction of 
acute phase proteins, IL-11 has a complex effect on immuno-
modulatory activities by reducing proinflammatory cytokines 
but interacting with other cytokines and regulatory molecules 
in the induction and amplification of autoimmune responses. 
Although it is not normally detected in systemic circulation, 
IL-11 is locally expressed and is present in  lesional areas 
Fig. 2 - IL-6 expression in SSc skin 
and internal organs. IL-6 is detected 
in the skin: in fibroblastic cells in 
the dermis, in the epidermis, and 
in perivascular cells (A). IL-6 expres-
sion is shown in the lung of a patient 
who developed PAH (B). IL-6 expres-
sion in glomeruli and renal tubules 
(C) and in SSc tissue from a post-
mortem specimen (D). IL-6 = inter-
leukin-6; PAH = pulmonary arterial 
hypertension; SSc = systemic scle-
rosis. Images courtesy of Khan K, 
Centre for Rheumatology and Con-
nective Tissue Diseases, University 
College London, London, UK.
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in atopic dermatitis (39). Limited data support increased 
transcriptomic IL-11 expression in lung fibroblasts in SSc- 
associated lung fibrosis, and recent data suggest that the der-
mal T cells derived from the IL-11/11R axis may be critical in 
Th17 differentiation in SSc (37, 40).
IL-31 has relatively low homology to IL-6 and does not 
share gp130 as a common receptor and signal transducer 
subunit in its receptor complex. It is implicated mainly in the 
pathogenesis of allergic diseases and is an important media-
tor of pruritus in some diseases. It has been proposed as a 
possible candidate biomarker in some cases of diffuse SSc, of 
which pruritus is a complication. Its receptor is expressed on 
fibroblasts, but there is no evidence that fibroblasts express 
the cytokine. IL-31 levels are elevated in the interstitial fluid 
of patients with SSc and must therefore be derived from non-
fibroblastic cells (38). Leukemia inhibitory factor is another 
member of the IL-6 family that shares its receptor with OSM. 
Levels are elevated in whole blood assays in patients with 
eosinophilic fasciitis, but studies of SSc have not yet been 
 reported (41).
There is a paucity of data on other IL-6–related cyto-
kines, including IL-27, neuropoietin, ciliary neurotrophic 
factor, and cardiotrophin 1, in SSc. IL-27 levels in sera, for 
example, were upregulated in patients with early-stage 
SSc with increased receptor expression in lesional fibro-
blasts (42), but this was not supported in a more recent 
study (24).
Conclusion
There is strong evidence to support the role of IL-6 in SSc, 
with emerging interest in its associated family members in 
early-stage diffuse scleroderma. Beyond an association with 
the induction of acute phase proteins and thrombopoiesis, 
correlation of levels of IL-6–related proteins with disease 
activity and survival outcome may help to stratify patient 
subgroups. The association between systemic or local IL-6 
expression and pathogenic potential in specific organ mani-
festations, particularly skin and lung fibrosis, and in PAH may 
inform future therapeutic strategies in SSc. Greater under-
standing of the ligand-receptor interaction and downstream 
signaling pathways (summarized in Fig. 3) define the role of 
IL-6 and its family members in SSc and may help to elucidate 
potential targeted therapies.
TABLE I - Cellular origin and relevant biology of IL-6 family members
Biology of IL-6 family members and related proteins – potential as biomarkers and pathogenic mediators in SSc
Protein Major cell of origin Potential target cells Disease associations studies in ssc
IL-6 Fibroblasts, naive and memory 
B lymphocytes, monocytes, 
CD4+ T cells, hepatocytes, pul-
monary artery smooth muscle 
cells, glomerular mesangial 
cells
Fibroblasts, macrophages, 
neutrophils, CD4 T cells, 
podocytes, hepatocytes, 
lymphocytes, endothelial cells, 
PASMCs
Rheumatoid arthritis, sclero-
derma, lung fibrosis, pulmo-
nary hypertension
Increased circulating and lo-
cal IL-6 levels correlate with 
disease activity in subset of SSc 
(6-8, 10, 19, 20). Differential 
IL-6 receptor expression may 
correlate with pattern of organ 
involvement (9)
IL-11 Fibroblasts, sub-epithelial 




Hematopoietic stem cells and 
megakaryocyte progenitor 
cells
Keloid, cancer, hemophilia, 
Crohn’s disease
Increased levels in lung fibro-
blasts on microarray profiling 
of lesional lung fibroblasts in 
SSc-associated lung fibrosis 
(37)
OSM Monocytes/macrophages, 
dendritic cells, neutrophils, and 
T lymphocytes
Epithelial, endothelial, smooth 
muscle cells, fibroblasts, chon-
drocytes, keratinocytes, tumor 
cell lines (with OSMRβ) and 
hematopoietic cells
Inflammatory bowel disease, 
scleroderma, sarcoidosis, 
COPD, breast cancer, osteosar-
coma
Increased local expression  
in lesional skin and  
bronchoalveolar lavage in  
SSc (33-36)
IL-31 Th2 and CD8+ T cells, mono-
cytes/macrophages, mast 
cells, dendritic cells, epidermal 
keratinocytes, and dermal 
fibroblasts
Mast cells, eosinophils, 
dendritic cells, keratino-
cytes, macrophages, dermal 
microvascular endothelial 
cells, colonic sub-epithelial 
myofibroblasts, neurons from 
dorsal root ganglia, various 
tumor cells lines
Cutaneous allergic diseases 
and atopic dermatitis, allergic 
asthma and rhinitis, inflamma-
tory bowel disease, hemato-
poietic and lymphoid tissue 
malignancies
Upregulated IL-31/IL-31R ex-
pression in lesional diffuse SSc 
skin (38)
LIF Fibroblasts, monocytes, mac-
rophages, T cells, osteoblasts, 
endometrial cells, hepatocytes, 
and retinal glial cells
Fibroblasts, monocytes/mac-
rophages
Eosinophilic fasciitis, cancer 
development, and progression
None
COPD = chronic obstructive pulmonary disease; IL = interleukin; LIF = leukemia inhibitory factor; OSM = oncostatin M; PASMCs = pulmonary aortic smooth 
muscle cells; R = receptor; SSc = systemic sclerosis.
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